Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.

van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Jun 5;170:161-168. doi: 10.1016/j.jpba.2019.03.043. Epub 2019 Mar 20.

PMID:
30925273
2.

The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive.

Zimmerman Y, Coelingh Bennink HJ, Wouters W, Ebes F, Fauser BC.

Eur J Contracept Reprod Health Care. 2013 Dec;18(6):489-500. doi: 10.3109/13625187.2013.822061. Epub 2013 Aug 14.

PMID:
23944295
3.

The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.

Zimmerman Y, Wouters W, Coelingh Bennink HJ.

Eur J Contracept Reprod Health Care. 2013 Jun;18(3):206-14. doi: 10.3109/13625187.2013.777831. Epub 2013 Apr 3.

PMID:
23550808
4.

Vasorelaxing effects of estetrol in rat arteries.

Hilgers RH, Oparil S, Wouters W, Coelingh Bennink HJ.

J Endocrinol. 2012 Oct;215(1):97-106. doi: 10.1530/JOE-12-0009. Epub 2012 Jul 13.

PMID:
22798015
5.

Mechanically induced calcium signaling in chondrocytes in situ.

Han SK, Wouters W, Clark A, Herzog W.

J Orthop Res. 2012 Mar;30(3):475-81. doi: 10.1002/jor.21536. Epub 2011 Aug 22.

6.

Delivery of a DNAzyme targeting c-myc to HT29 colon carcinoma cells using a gold nanoparticulate approach.

Tack F, Noppe M, Van Dijck A, Dekeyzer N, Van Der Leede BJ, Bakker A, Wouters W, Janicot M, Brewster ME.

Pharmazie. 2008 Mar;63(3):221-5.

PMID:
18444511
7.

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

Angibaud P, Mevellec L, Meyer C, Bourdrez X, Lezouret P, Pilatte I, Poncelet V, Roux B, Merillon S, End DW, Van Dun J, Wouters W, Venet M.

Eur J Med Chem. 2007 May;42(5):702-14. Epub 2007 Jan 9.

PMID:
17316920
8.

R176502, a new bafilolide metabolite with potent antiproliferative activity from a novel Micromonospora species.

Laakso JA, Mocek UM, Van Dun J, Wouters W, Janicot M.

J Antibiot (Tokyo). 2003 Nov;56(11):909-16.

9.

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Angibaud P, Bourdrez X, End DW, Freyne E, Janicot M, Lezouret P, Ligny Y, Mannens G, Damsch S, Mevellec L, Meyer C, Muller P, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9.

PMID:
14643327
10.

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

Angibaud P, Saha AK, Bourdrez X, End DW, Freyne E, Lezouret P, Mannens G, Mevellec L, Meyer C, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4361-4.

PMID:
14643326
11.

Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library.

Hitoshi Y, Gururaja T, Pearsall DM, Lang W, Sharma P, Huang B, Catalano SM, McLaughlin J, Pali E, Peelle B, Vialard J, Janicot M, Wouters W, Luyten W, Bennett MK, Anderson DC, Payan DG, Lorens JB, Bogenberger J, Demo S.

Chem Biol. 2003 Oct;10(10):975-87. No abstract available.

PMID:
14583264
12.

Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.

Gunning WT, Kramer PM, Lubet RA, Steele VE, End DW, Wouters W, Pereira MA.

Clin Cancer Res. 2003 May;9(5):1927-30.

13.

5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.

Angibaud P, Bourdrez X, Devine A, End DW, Freyne E, Ligny Y, Muller P, Mannens G, Pilatte I, Poncelet V, Skrzat S, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 May 5;13(9):1543-7.

PMID:
12699751
14.

Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.

De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van Heusden J.

J Pharmacol Exp Ther. 2003 Feb;304(2):881-8.

PMID:
12538846
15.

Neurotrophic and antileukemic daphnane diterpenoids from Synaptolepis kirkii.

He W, Cik M, Van Puyvelde L, Van Dun J, Appendino G, Lesage A, Van der Lindin I, Leysen JE, Wouters W, Mathenge SG, Mudida FP, De Kimpe N.

Bioorg Med Chem. 2002 Oct;10(10):3245-55.

PMID:
12150870
16.

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity.

Van Heusden J, Van Ginckel R, Bruwiere H, Moelans P, Janssen B, Floren W, van der Leede BJ, van Dun J, Sanz G, Venet M, Dillen L, Van Hove C, Willemsens G, Janicot M, Wouters W.

Br J Cancer. 2002 Feb 12;86(4):605-11.

17.

Synthesis and anti-angiogenic activity of 6-(1,2,4-thiadiazol-5-yl)-3-amino pyridazine derivatives.

Bongartz JP, Stokbroekx R, Van der Aa M, Luyckx M, Willems M, Ceusters M, Meerpoel L, Smets G, Jansen T, Wouters W, Bowden C, Valletta L, Herb M, Tominovich R, Tuman R.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):589-91. Erratum in: Bioorg Med Chem Lett. 2002 Apr 8;12(7):1133-4.

PMID:
11844678
18.

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

Cancer Res. 2001 Jan 1;61(1):131-7.

19.

Prenatal diagnosis of facial clefting as part of the oculo-auriculo-vertebral spectrum.

Witters I, Schreurs J, Van Wing J, Wouters W, Fryns JP.

Prenat Diagn. 2001 Jan;21(1):62-4.

PMID:
11180244
20.

Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.

Freyne E, Raeymaekers A, Venet M, Sanz G, Wouters W, De Coster R, Wauwe JV.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):267-72.

PMID:
9871667
21.
22.

All-trans-retinoic acid metabolites significantly inhibit the proliferation of MCF-7 human breast cancer cells in vitro.

Van heusden J, Wouters W, Ramaekers FC, Krekels MD, Dillen L, Borgers M, Smets G.

Br J Cancer. 1998;77(1):26-32.

23.

Induction of the oxidative catabolism of retinoid acid in MCF-7 cells.

Krekels MD, Verhoeven A, van Dun J, Cools W, Van Hove C, Dillen L, Coene MC, Wouters W.

Br J Cancer. 1997;75(8):1098-104.

24.

Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro.

Van heusden J, Borgers M, Ramaekers F, Xhonneux B, Wouters W, De Coster R, Smets G.

Eur J Cell Biol. 1996 Sep;71(1):89-98.

PMID:
8884182
25.

Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors.

Krekels MD, Zimmerman J, Janssens B, Van Ginckel R, Cools W, Van Hove C, Coene MC, Wouters W.

Prostate. 1996 Jul;29(1):36-41.

PMID:
8685053
26.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
27.

Vorozole, a specific non-steroidal aromatase inhibitor.

Wouters W, Snoeck E, De Coster R.

Breast Cancer Res Treat. 1994;30(1):89-94. Review.

PMID:
7726994
28.

Adamantinoma of the tibia: MRI documentation.

Vanhoenacker F, Van Ongeval C, Ceulemans R, Wouters W, Lateur L.

J Belge Radiol. 1993 Jun;76(3):154-6.

PMID:
8253651
29.

Pharmacology of vorozole.

Wouters W, Van Ginckel R, Krekels M, Bowden C, De Coster R.

J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):617-21.

PMID:
8386540
30.

Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown.

De Coster R, Wouters W, Van Ginckel R, End D, Krekels M, Coene MC, Bowden C.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):197-201. Review.

PMID:
1525060
31.
32.

Aromatase inhibition by R 83 842, the dextro isomer of R 76 713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice.

Krekels MD, Wouters W, Van Ginckel R, Janssens B, Callens M, De Coster R.

J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):761-4.

PMID:
1562551
33.

Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice.

Krekels MD, Wouters W, De Coster R, Van Ginckel R, Leonaers A, Janssen PA.

J Steroid Biochem Mol Biol. 1991 Apr;38(4):415-22.

PMID:
2031856
34.
35.
36.

Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo.

Wouters W, De Coster R, van Dun J, Krekels MD, Dillen A, Raeymaekers A, Freyne E, Van Gelder J, Sanz G, Venet M, et al.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1049-54.

PMID:
2178362
37.

New non-steroidal aromatase inhibitors: focus on R76713.

De Coster R, Wouters W, Bowden CR, Vanden Bossche H, Bruynseels J, Tuman RW, Van Ginckel R, Snoeck E, Van Peer A, Janssen PA.

J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):335-41. Review.

PMID:
2257238
38.

Potency and selectivity of the aromatase inhibitor R 76,713. A study in human ovarian, adipose stromal, testicular and adrenal cells.

Wouters W, De Coster R, Beerens D, Doolaege R, Gruwez JA, Van Camp K, Van Der Pas H, van Herendael B.

J Steroid Biochem. 1990 Jun;36(1-2):57-65.

PMID:
2362449
39.

Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat.

Dreteler GH, Wouters W, Saxena PR.

Eur J Pharmacol. 1990 May 16;180(2-3):339-49.

PMID:
2142096
40.

Aromatase inhibition by R 76 713: a kinetic analysis in rat ovarian homogenates.

Krekels MD, Wouters W, De Coster R.

Steroids. 1990 Feb;55(2):69-73.

PMID:
2326830
41.

Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.

Van Ginckel R, De Coster R, Wouters W, Vanherck W, van der Veer R, Goeminne N, Jagers E, Van Cauteren H, Wouters L, Distelmans W, et al.

Prostate. 1990;16(4):313-23.

PMID:
2371176
42.

R 75251, a new inhibitor of steroid biosynthesis.

Bruynseels J, De Coster R, Van Rooy P, Wouters W, Coene MC, Snoeck E, Raeymaekers A, Freyne E, Sanz G, Vanden Bussche G, et al.

Prostate. 1990;16(4):345-57.

PMID:
2164659
43.

Endocrine and antitumoral effects of R76713 in rats.

De Coster R, Van Ginckel R, Wouters W, Goeminne N, Vanherck W, Byloos M.

J Enzyme Inhib. 1990;4(2):159-67.

PMID:
2098522
44.

Systemic and regional hemodynamic effects of the putative 5-HT1A receptor agonist flesinoxan in the cat.

Dreteler GH, Wouters W, Saxena PR.

J Cardiovasc Pharmacol. 1989 Nov;14(5):770-6.

PMID:
2481192
45.

R 76713, a new specific non-steroidal aromatase inhibitor.

Wouters W, De Coster R, Krekels M, van Dun J, Beerens D, Haelterman C, Raeymaekers A, Freyne E, Van Gelder J, Venet M, et al.

J Steroid Biochem. 1989 Jun;32(6):781-8.

PMID:
2755126
46.

Inhibitory action of androstenedione on the proliferation and cell cycle kinetics of aromatase-free MXT and MCF-7 mammary tumour cell lines.

Kiss R, de Launoit Y, Wouters W, Deslypere JP, Lescrainier JP, Paridaens R, Vokaer A, Decoster R, Pasteels JL.

Eur J Cancer Clin Oncol. 1989 May;25(5):837-43.

PMID:
2737220
47.

Aromatase inhibition by R 76713: experimental and clinical pharmacology.

Wouters W, De Coster R, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Amery WK, Janssen PA.

J Steroid Biochem. 1989;34(1-6):427-30.

PMID:
2696850
48.

Comparative effects of etomidate and its fluoro analogue, R 8110 on testicular, adrenal and ovarian steroid biosynthesis.

De Coster R, Wouters W, Beerens D, Haelterman C, Doolaege R, Goeminne N, Krekels M.

J Vet Pharmacol Ther. 1988 Dec;11(4):345-53.

PMID:
3210261
50.

Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors.

Wouters W, Tulp MT, Bevan P.

Eur J Pharmacol. 1988 May 10;149(3):213-23.

PMID:
2842163

Supplemental Content

Loading ...
Support Center